ALNYLAM PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 147 USD | +0.82% |
|
+0.44% | -23.01% |
| Apr. 08 | Sector Update: Health Care Stocks Flat to Higher Premarket Monday | MT |
| Apr. 08 | Sector Update: Health Care | MT |
Presenter SpeechEliana Merle (Analysts)Good morning, everyone. Thank you so much for joining u...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
145.8
USD
Average target price
220
USD
Spread / Average Target
+50.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -23.01% | 18.44B | |
| +1.85% | 42.11B | |
| +48.83% | 40.08B | |
| +7.75% | 40B | |
| -10.82% | 26.87B | |
| +7.59% | 24.58B | |
| +2.40% | 11.94B | |
| +30.22% | 11.66B | |
| +7.35% | 11.01B | |
| -17.02% | 9.87B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Transcript : Alnylam Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-25-2022 10
